Oligomerix, Inc. news
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer`s Disease (CTAD) conference and at the Society for Neuroscience’s (SfN) 50th annual meeting Neuroscience 2021.
A study was conducted in
- Phase 1 trial of tau-targeting lead program planned to begin in 3Q22
- Funding will also support the characterization of the Company’s second-generation assets
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an extension of its Series B funding round, raising $2.7 mill
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.” The ‘776 patent further strengthens the company’s intellectual property position and coverage for their
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer`s Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings in November 2022.
“With millions of Americans suffering from Alzheimer’s disea
- Award to support Phase 1b studies to evaluate tau self-association small molecule inhibitor
- In August, company announced a $3.35M grant from NIH to support a Phase 1a clinical trial
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $2.49 million from the National Institute on Aging of the National Institutes of